Drugs used in drug-eluting stents (DES) to inhibit proliferation of smooth muscle cells (SMCs) also limit re-endothelialization at the site of stent implantation . Thus, treated patients face an increased risk of late-stent thrombosis. Avoiding this adverse side effect represents one of the major challenges in the design of next-generation DES.
- Bioengineering Division
Dynamics of Arterial Wall Transport for Small Hydrophobic Drugs
- Views Icon Views
- Share Icon Share
- Search Site
Bozsak, F, Chomaz, J, & Barakat, AI. "Dynamics of Arterial Wall Transport for Small Hydrophobic Drugs." Proceedings of the ASME 2012 Summer Bioengineering Conference. ASME 2012 Summer Bioengineering Conference, Parts A and B. Fajardo, Puerto Rico, USA. June 20–23, 2012. pp. 565-566. ASME. https://doi.org/10.1115/SBC2012-80541
Download citation file: